BACKGROUND AND OBJECTIVES: Elevated serum vitamin D with hypercalciuria can result in nephrocalcinosis and nephrolithiasis. This study evaluated the cause of excess 1,25-dihydroxycholecalciferol (1α,25(OH)2D3) in the development of those disorders in two individuals. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two patients with elevated vitamin D levels and nephrocalcinosis or nephrolithiasis were investigated at the National Institutes of Health (NIH) Clinical Center and the NIH Undiagnosed Diseases Program, by measuring calcium, phosphate, and vitamin D metabolites, and by performing CYP24A1 mutation analysis. RESULTS: Both patients exhibited hypercalciuria, hypercalcemia, low parathyroid hormone, elevated vitamin D (1α,25(OH)2D3), normal 25-OHD3, decreased 24,25(OH)2D, and undetectable activity of 1,25(OH)2D-24-hydroxylase (CYP24A1), the enzyme that inactivates 1α,25(OH)2D3. Both patients had bi-allelic mutations in CYP24A1 leading to loss of function of this enzyme. On the basis of dbSNP data, the frequency of predicted deleterious bi-allelic CYP24A1 variants in the general population is estimated to be as high as 4%-20%. CONCLUSIONS: The results of this study show that 1,25(OH)2D-24-hydroxylase deficiency due to bi-allelic mutations in CYP24A1 causes elevated serum vitamin D, hypercalciuria, nephrocalcinosis, and renal stones.
BACKGROUND AND OBJECTIVES: Elevated serum vitamin D with hypercalciuria can result in nephrocalcinosis and nephrolithiasis. This study evaluated the cause of excess 1,25-dihydroxycholecalciferol (1α,25(OH)2D3) in the development of those disorders in two individuals. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two patients with elevated vitamin D levels and nephrocalcinosis or nephrolithiasis were investigated at the National Institutes of Health (NIH) Clinical Center and the NIH Undiagnosed Diseases Program, by measuring calcium, phosphate, and vitamin D metabolites, and by performing CYP24A1 mutation analysis. RESULTS: Both patients exhibited hypercalciuria, hypercalcemia, low parathyroid hormone, elevated vitamin D (1α,25(OH)2D3), normal 25-OHD3, decreased 24,25(OH)2D, and undetectable activity of 1,25(OH)2D-24-hydroxylase (CYP24A1), the enzyme that inactivates 1α,25(OH)2D3. Both patients had bi-allelic mutations in CYP24A1 leading to loss of function of this enzyme. On the basis of dbSNP data, the frequency of predicted deleterious bi-allelic CYP24A1 variants in the general population is estimated to be as high as 4%-20%. CONCLUSIONS: The results of this study show that 1,25(OH)2D-24-hydroxylase deficiency due to bi-allelic mutations in CYP24A1 causes elevated serum vitamin D, hypercalciuria, nephrocalcinosis, and renal stones.
Authors: Andrew Dauber; Thutrang T Nguyen; Etienne Sochett; David E C Cole; Ronald Horst; Steven A Abrams; Thomas O Carpenter; Joel N Hirschhorn Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Peter J Tebben; Dawn S Milliner; Ronald L Horst; Peter C Harris; Ravinder J Singh; Yanhong Wu; John W Foreman; Paul R Chelminski; Rajiv Kumar Journal: J Clin Endocrinol Metab Date: 2012-02-15 Impact factor: 5.958
Authors: Karl P Schlingmann; Justyna Ruminska; Martin Kaufmann; Ismail Dursun; Monica Patti; Birgitta Kranz; Ewa Pronicka; Elzbieta Ciara; Teoman Akcay; Derya Bulus; Elisabeth A M Cornelissen; Aneta Gawlik; Przemysław Sikora; Ludwig Patzer; Matthias Galiano; Veselin Boyadzhiev; Miroslav Dumic; Asaf Vivante; Robert Kleta; Benjamin Dekel; Elena Levtchenko; René J Bindels; Stephan Rust; Ian C Forster; Nati Hernando; Glenville Jones; Carsten A Wagner; Martin Konrad Journal: J Am Soc Nephrol Date: 2015-06-05 Impact factor: 10.121
Authors: Martin Kaufmann; J Christopher Gallagher; Munro Peacock; Karl-Peter Schlingmann; Martin Konrad; Hector F DeLuca; Rita Sigueiro; Borja Lopez; Antonio Mourino; Miguel Maestro; René St-Arnaud; Joel S Finkelstein; Donald P Cooper; Glenville Jones Journal: J Clin Endocrinol Metab Date: 2014-03-26 Impact factor: 5.958
Authors: Colin Patrick Hawkes; Dong Li; Hakon Hakonarson; Kevin E Meyers; Kenneth E Thummel; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2017-05-01 Impact factor: 5.958
Authors: Thomas P Jacobs; Martin Kaufman; Glenville Jones; Rajiv Kumar; Karl-Peter Schlingmann; Sue Shapses; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2014-01-13 Impact factor: 5.958